



Background

- Catheter-associated UTI is a symptomatic bladder or kidney infection in a person with a catheter
- Bacteria are more likely to be present in urine the longer a catheter is in place (after 1 month most people have bacteriuria)
- · Antibiotic treatment is not routinely needed for asymptomatic bacteriuria in people with a catheter

Self-care

- Advise paracetamol for pain
- Advise drinking enough fluids to avoid dehydration

Antibiotics

- · When prescribing antibiotics, take account of severity of symptoms, risk of complications, previous urine culture and susceptibility results, previous antibiotic use which may have led to resistant bacteria, and local antimicrobial resistance data
- · Give oral antibiotics firstline if people can take oral medicines, and the severity of their condition does not require intravenous antibiotics
- Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible

Prevention

- Do not routinely offer antibiotic prophylaxis to people with a short-term or long-term catheter
- Advise seeking medical help if symptoms of acute UTI develop

Choice of antibioti	c for non-pregnant women and men aged 16 years and over	
Antibiotic	Dosage and course length	
First-choice oral antibiotics if no upper UTI symptoms		
Nitrofurantoin (if eGFR 45 ml/min or more)	100 mg modified-release twice a day (or if unavailable, 50 mg four times a day) for 7 days	
Trimethoprim (if low risk of resistance)	200 mg twice a day for 7 days	
Amoxicillin (only if culture results available and susceptible)	500 mg three times a day for 7 days	
Second-choice oral antibiotic if no upper UTI symptoms (when first choice not suitable)		
Pivmecillinam (a penicillin)	400 mg initial dose then 200 mg three times a day for a total of 7 days	
First-choice oral antibiotics if upper UTI symptoms		
Cefalexin	500 mg twice or three times a day (up to 1 to 1.5 g three or four times a day for severe infections) for 7 to 10 days	
Co-amoxiclav (only if culture results available and susceptible)	500/125 mg three times a day for 7 to 10 days	
Trimethoprim (only if culture results available and susceptible)	200 mg twice a day for 14 days	
Ciprofloxacin (only if other first-choice antibiotics are unsuitable)	500 mg twice a day for 7 days	

Choice of antibiotic for non-pregnant women and men aged 16 years and over, continued		
Antibiotic	Dosage and course length	
First-choice intravenous antibiotics (if vomiting, unable to take oral antibiotics, or severely unwell). Antibiotics may be combined if susceptibilty or sepsis is a concern		
Co-amoxiclav (only in combination or if culture results available and susceptible)	1.2 g three times a day	
Cefuroxime	750 mg to 1.5 g three or four times a day	
Ceftriaxone	1 to 2 g once a day	
Gentamicin	Initially 5 mg/kg to 7 mg/kg once a day, subsequent doses adjusted according to serum gentamicin concentration	
Amikacin	Initially 15 mg/kg once a day (maximum per dose 1.5 g once a day), subsequent doses adjusted according to serum amikacin concentration (maximum 15 g per course)	
Ciprofloxacin (only if other first-choice antibiotics are unsuitable)	400 mg twice or three times a day	

Second-choice intravenous antibiotics: consult local microbiologist

Notes

For all antibiotics: see BNF for appropriate use and dosing in specific populations, for example, hepatic impairment, renal impairment, breastfeeding, and administering intravenous antibiotics. Check any previous urine culture and susceptibility results and antibiotic prescribing, and choose antibiotics accordingly.

For **intravenous antibiotics**: review by 48 hours and consider stepping down to oral antibiotics where possible.


For **nitrofurantoin**: this option may be used with caution if eGFR is 30 to 44 ml/min to treat uncomplicated lower UTI caused by suspected or proven multidrug resistant bacteria, and only if potential benefit outweighs risk (see <u>BNF information on nitrofurantoin</u>).

For nitrofurantoin and pivmecillinam: these options are only licensed for uncomplicated lower UTIs, and are not suitable for people with upper UTI symptoms or a blocked catheter.

For **trimethoprim**: a lower risk of resistance is likely if not used in the past 3 months, previous urine culture suggests susceptibility (but this was not used), and in younger people in areas where data suggests low resistance. Higher risk of resistance is likely with recent use and in older people in care homes.

(!) Warning: for ciprofloxacin, see MHRA January 2024 advice for restrictions and precautions for using fluoroquinolone antibiotics because of the risk of disabling and potentially long-lasting or irreversible side effects. These fluoroquinolones must now only be prescribed when other commonly recommended antibiotics are inappropriate.

For gentamicin and amikacin: therapeutic drug monitoring and assessment of renal function is required for adjusting doses (see BNF information on gentamicin and BNF information on amikacin).



Choice of antibiotic for pregnant women aged 12 years and over

Antibiotic Dosage and course length

First-choice oral antibiotic

Cefalexin 500 mg twice or three times a day (up to 1 to 1.5 g three or four times a day for severe infections) for 7 to 10 days

First-choice intravenous antibiotic (if vomiting, unable to take oral antibiotics, or severely unwell)


Cefuroxime 750 mg to 1.5 g three or four times a day

Second-choice antibiotics or combining antibiotics if susceptibility or sepsis a concern: consult local microbiologist

Notes

For **all antibiotics**: see <u>BNF</u> for appropriate use and dosing in specific populations, for example, hepatic impairment, renal impairment, breastfeeding, and administering intravenous antibiotics. Check any previous urine culture and **susceptibility results** and antibiotic prescribing, and choose antibiotics accordingly.

For intravenous antibiotics: review by 48 hours and consider stepping down to oral antibiotics where possible.



infections)

infections)

Choice of antibiotic for children and young people under 16 years		
Antibiotic	Dosage and course length	
Refer children under 3 months to paediatric specialist and treat with intravenous antibiotics in line with the NICE guideline on fever in under 5s		
Children aged 3 months and over: first-choice oral antibiotics		
Trimethoprim (if low risk of resistance)	3 to 5 months, 4 mg/kg (maximum 200 mg per dose) or 25 mg twice a day for 7 to 10 days; 6 months to 5 years, 4 mg/kg (maximum 200 mg per dose) or 50 mg twice a day for 7 to 10 days; 6 to 11 years, 4 mg/kg (maximum 200 mg per dose) or 100 mg twice a day for 7 to 10 days; 12 to 15 years, 200 mg twice a day for 7 to 10 days	
Amoxicillin (only if culture results available and susceptible)	3 to 11 months, 125 mg three times a day for 7 to 10 days; 1 to 4 years, 250 mg three times a day for 7 to 10 days; 5 to 15 years, 500 mg three times a day for 7 to 10 days	
	3 to 11 months, 12.5 mg/kg or 125 mg twice a day for 7 to 10 days (25 mg/kg two to four times a day [maximum 1 g per dose four times a day] for severe infections) 1 to 4 years, 12.5 mg/kg twice a day or 125 mg three times a day for 7 to 10 days (25 mg/kg two to four times a day [maximum 1 g per dose four times a day] for severe	

Co-amoxiclav (only if culture results available and susceptible)

Cefalexin

3 to 11 months, 0.25 ml/kg of 125/31 suspension three times a day for 7 to 10 days (dose doubled in severe infection)

12 to 15 years, 500 mg twice or three times a day (up to 1 to 1.5 g three or four times a day for severe infections) for 7 to 10 days

1 to 5 years, 0.25 ml/kg of 125/31 suspension or 5 ml of 125/31 suspension three times a day for 7 to 10 days (dose doubled in severe infection)

5 to 11 years, 12.5 mg/kg twice a day or 250 mg three times a day for 7 to 10 days (25 mg/kg two to four times a day [maximum 1 g per dose four times a day] for severe

6 to 11 years, 0.15 ml/kg of 250/62 suspension or 5 ml of 250/62 suspension three times a day for 7 to 10 days (dose doubled in severe infection)

12 to 15 years, 250/125 mg or 500/125 mg three times a day for 7 to 10 days


Children aged 3 months and over: first-choice intravenous antibiotics (if vomiting, unable to take oral antibiotics or severely unwell). Antibiotics may be combined if susceptibility or sepsis a concern

combin	results confirm	3 months to 15 years, 30 mg/kg three times a day (maximum 1.2 g three times a day)	
Cefuro	VIME	3 months to 15 years, 20 mg/kg three times a day (maximum 750 mg per dose), increased to 50 to 60 mg/kg three or four times a day (maximum 1.5 g per dose) for severe infections	
Ceftria	xone	3 months to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day); 9 to 11 years (50 kg and above), 1 to 2 g once a day; 12 to 15 years, 1 to 2 g once a day	
Gentam	nicin	Initially 7 mg/kg once a day, subsequent doses adjusted according to serum gentamicin concentration	
Amikac	cin	Initially 15 mg/kg once a day, subsequent doses adjusted according to serum amikacin concentration	

Children aged 3 months and over: for second-choice intravenous antibiotics, consult local microbiologist

Notes

See over page.



Choice of antibiotic for children and young people under 16 years, continued

Notes

For **all antibiotics**: see <u>BNF for children</u> (BNFC) for appropriate use and dosing in specific populations, for example, hepatic impairment, renal impairment, and administering intravenous antibiotics. For prescribing in pregnancy, refer to the table on choice of antibiotic for pregnant women aged 12 and over. Age bands apply to average size and, in practice, age bands will be used with other factors such as the severity of the condition and the child's size. Check any previous urine culture and **susceptibility results** and antibiotic prescribing, and choose antibiotics accordingly. If a child or young person is receiving prophylactic antibiotics, treatment should be with a different antibiotic not a higher dose of the same antibiotic.

For **intravenous antibiotics**: review by 48 hours and consider stepping down to oral antibiotics where possible for a total antibiotic course of 10 days. If intravenous treatment is not possible, consider intramuscular treatment, if suitable.

For trimethoprim: a lower risk of resistance is likely if not used in the past 3 months, previous urine culture suggests susceptibility (but this was not used), and in younger people in areas where data suggests low resistance. Higher risk of resistance is likely with recent use.

For **gentamicin** and **amikacin**: therapeutic drug monitoring and assessment of renal function is required for adjusting doses (see <u>BNFC information on gentamicin</u> and <u>BNFC information</u> on amikacin).

